Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.

Ann Hematol · 2010 · PMC2940014 · PMID 20532504

Europe PMC DOI

hedged sentence

0.0578

closest p · 1.2× alpha

0.0578

boldest claim

The sentences

showed a trendp = 0.0578so close (0.05 < p ≤ 0.1)

MDR1/3435(C > T), which was in Hardy–Weinberg equilibrium, showed a trend of association with PFS ( p = 0.0578), response rate ( p = 0.0782) and TTP ( p = 0.0923) in PLD + bortezomib patients, though no correlation was found in the bortezomib arm.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.